Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS Miss
May 11, 2015 7:52 AM EDTCantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) following a 1Q15 EPS miss. JAZZ reported in-line revenue of $309M, but missed the adjusted diluted EPS with $1.99 (vs. $2.14 estimates). Cantor Fitzgerald said that they... More
Guggenheim Securities Remains Bullish in Wake of Jazz Pharmaceuticals (JAZZ) 1Q15 EPS Miss
May 8, 2015 8:46 AM EDTGuggenheim Securities maintains a Buy status on Jazz Pharmaceuticals, PLC (NASDAQ: JAZZ), with a price target set at $210. This follows an EPS miss from JAZZ in 1Q15. JAZZ reported 1Q15 adjusted diluted EPS of $1.99. This came in $0.15 lower than consensus and $0.18 lower than Guggenheim estimated. Guggenheim believes that... More
